Table 3.
Cell type | Type of study | Experimental design | Cell dosage | Measurement | Results | Ref. |
Autologous | Case series (n = 61); Final follow up: 6 mo | Phase I/II study | Not mentioned | VAS, WOMAC and X-ray | Significantly reductions in knee pain and increased quality of life at 6 mo follow-up | Garay-Mendoza et al[68], 2018 |
Autologous | Case series (n = 13); Final follow up: 24 mo | Phase I/II study | Intra-articular injection of 30.5 × 106 MSCs | MRI and KOOS | After intra-articular injection with BM-MSCs had significantly improved the KOOS and knee cartilage thickness | Al-Najar et al[69], 2017 |
Allogeneic | Case series (n = 60); Final follow up: 24 mo | Double-blind, multicentric, placebo-controlled, phase II study | Four dose levels were studied in this trial: 25 × 106, 50 × 106, 75 × 106, and 150 × 106 | VAS, ICOAP and WOMAC | A 25 × 106 cell dose may be the most effective among the doses; WOMAC, ICOAP, and VAS scores decreased by the time of the final follow-up period | Gupta et al[70], 2016 |
Autologous | Case series (n = 30); Final follow up: 12 mo | Double-blind, multicentric, phase I/II study | Two dose levels were studied in this trial: 10 × 106 and 100 × 106 | VAS, WOMAC, X-ray and MRI | A clinical and functional improvement of knee OA by the injection of 100 × 106 cell dose; Improvement of pain and knee function of OA patients at 12 mo follow-up | Lamo-Espinosa et al[71], 2016 |
Autologous | Case series (n = 4); Final follow up: 60 mo | Phase I study | Intra-articular injection of 8-9 × 106 MSCs | Walking time, X-ray and VAS | Earlier transplantation may give better results in long-term follow-up | Soler et al[72], 2016 |
Allogeneic | Case series (n = 30); Final follow up: 12 mo | Multicentric, phase I/II study | Intra-articular injection of 40 × 106 MSCs | VAS, WOMAC, and LEQUESNE; MRI | Significantly improves cartilage quality and provides pain relief | Vega et al[73], 2015 |
Autologous | Case series (n = 30); Final follow up: 30 mo | Not mentioned | Intra-articular injection of 0.5 × 106 MSCs | Walking distance, VAS, WOMAC and MRI | Significantly improves cartilage quality and knee function, and reduces pain level | Emadedin et al[74], 2015 |
Autologous | Case series (n = 4); Final follow up: 60 mo | Phase I study,open label | Intra-articular injection of 8 × 106 MSCs | VAS, Knee motion, Range, X-ray | Earlier transplantation may give better results in long-term follow-up | Davatch et al[75], 2016 |
VAS: Visual Analogue Scale/Score; WOMAC: The Western Ontario and McMaster Universities; MRI: Magnetic resonance imaging; MSCs: Mesenchymal stem cells; KOOS: Knee Injury and Osteoarthritis Outcome; BM-MSCs: Bone marrow-derived mesenchymal stem cells; ICOAP: The Intermittent and Constant Osteoarthritis Pain Score; OA: Osteoarthritis.